최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기생물정신의학 = Korean journal of biological psychiatry, v.24 no.3, 2017년, pp.134 - 141
곽숙영 (동국대학교 일산병원 정신건강의학과) , 윤탁 (동국대학교 일산병원 정신건강의학과) , 이남영 (동국대학교 일산병원 정신건강의학과) , 정인원 (동국대학교 일산병원 정신건강의학과) , 김세현 (동국대학교 일산병원 정신건강의학과)
Objectives A retrospective case series study was conducted to investigate the clinical characteristics of psychotic disorders induced by appetite suppressants, phentermine and phendimetrazine. Methods A retrospective electronic medical record review identified 5 admitted patients who had psychotic s...
* AI 자동 식별 결과로 적합하지 않은 문장이 있을 수 있으니, 이용에 유의하시기 바랍니다.
핵심어 | 질문 | 논문에서 추출한 답변 |
---|---|---|
Phentermine으로 인한 위험성은 무엇이 있는가? | Amphetamine은 남용 가능성, 심혈관계 부작용, 뇌출혈 위험성 등을 이유로 비만치료에 더 이상 사용되지 않는다.4) Phentermine 또한 교감신경흥분 작용 때문에 고혈압, 빈맥, 초조, 불면 등의 부작용이 있을 수 있고, 이론적으로 의존, 내성의 위험성이 있다.5) 미국 식품의약품안전청(The Food and Drug Administration, FDA)에서는 phentermine을 일일 30 mg(phentermine HCl 37. | |
식욕 억제제 중 1세대 약물이 더 이상 사용되지 않는 이유는 무엇인가? | Amphetamine은 남용 가능성, 심혈관계 부작용, 뇌출혈 위험성 등을 이유로 비만치료에 더 이상 사용되지 않는다.4) Phentermine 또한 교감신경흥분 작용 때문에 고혈압, 빈맥, 초조, 불면 등의 부작용이 있을 수 있고, 이론적으로 의존, 내성의 위험성이 있다. | |
식욕억제제는 무엇인가? | 비만치료 약물 중 식욕억제제는 중추신경계의 노르에피네프린, 세로토닌 등의 신경전달물질에 작용하여 식이량을 감소시킨다. 식욕억제제에 속하는 교감신경흥분제(sympathomimetics)는 노르에피네프린처럼 작용하는 약제이며, 1세대 약물로 amphetamine이 있다. |
Bray GA. Drug insight: appetite suppressants. Nat Clin Pract Gastroenterol Hepatol 2005;2:89-95.
Rothman RB, Baumann MH, Dersch CM, Romero DV, Rice KC, Carroll FI, et al. Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse 2001;39:32-41.
Rothman RB, Baumann MH. Therapeutic potential of monoamine transporter substrates. Curr Top Med Chem 2006;6:1845-1859.
Kang JG, Park CY. Anti-obesity drugs: a review about their effects and safety. Diabetes Metab J 2012;36:13-25.
Rueda-Clausen CF, Padwal RS, Sharma AM. New pharmacological approaches for obesity management. Nat Rev Endocrinol 2013;9: 467-478.
Kim MK. Behavioral intervention and anti-obesity drug therapy. Korean J Med 2013;84:624-628.
NCD Risk Factor Collaboration (NCD-RisC). Trends in adult bodymass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19.2 million participants. Lancet 2016;387:1377-1396.
INCB.org [homepage on the Internet]. Vienna: International Narcotics Control Board Online Resources, Inc.;c1995-2017[updated 2015 Mar; cited 2017 Mar 8]. Available from: http://www.incb.org/documents/Psychotropics/technical-publications/2015/Technical_PSY_2015_ENG.pdf.
Boileau I, Dagher A, Leyton M, Gunn RN, Baker GB, Diksic M, et al. Modeling sensitization to stimulants in humans: an [11C]raclopride/positron emission tomography study in healthy men. Arch Gen Psychiatry 2006;63:1386-1395.
Bramness JG, Gundersen OH, Guterstam J, Rognli EB, Konstenius M, Loberg EM, et al. Amphetamine-induced psychosis--a separate diagnostic entity or primary psychosis triggered in the vulnerable? BMC Psychiatry 2012;12:221.
McKetin R, Lubman DI, Baker AL, Dawe S, Ali RL. Dose-related psychotic symptoms in chronic methamphetamine users: evidence from a prospective longitudinal study. JAMA Psychiatry 2013;70: 319-324.
Rubin RT. Acute psychotic reaction following ingestion of phentermine. Am J Psychiatry 1964;120:1124-1125.
Alexander J, Cheng YH, Choudhary J, Dinesh A. Phentermine (Duromine) precipitated psychosis. Aust N Z J Psychiatry 2011;45:684- 685.
Devan GS. Phentermine and psychosis. Br J Psychiatry 1990;156: 442-443.
Raison CL, Klein HM. Psychotic mania associated with fenfluramine and phentermine use. Am J Psychiatry 1997;154:711.
Glatt MM. Psychosis and addiction to phenmetrazine. The Lancet 1959;274:348-349.
Lee JM, Lee KU, Jhoo JH, Park JI. Two cases of psychotic disorder following phendimetrazine use. Korean J Psychopharmacol 2010; 21:95-98.
Yun JA, Park WR, Yu JC, Choi KS. A case of Phendimetrazine induced-psychotic disorder and dependence.J Korean Neuropsychiatr Assoc 2013;52:402-405.
Kim KK, Cho HJ, Kang HC, Youn BB, Lee KR. Effects on weight reduction and safety of short-term phentermine administration in Korean obese people. Yonsei Med J 2006;47:614-625.
Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet 2000;356:1255-1259.
American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-5TM). 5th edition. Arlington, VA: American Psychiatric Association;2013. p.110-111.
Wang LJ, Lin SK, Chen YC, Huang MC, Chen TT, Ree SC, et al. Differences in clinical features of methamphetamine users with persistent psychosis and patients with schizophrenia. Psychopathology 2016;49:108-115.
Fraser S, Hides L, Philips L, Proctor D, Lubman DI. Differentiating first episode substance induced and primary psychotic disorders with concurrent substance use in young people. Schizophr Res 2012;136: 110-115.
Volkow ND, Wang GJ, Fowler JS, Tomasi D, Telang F. Addiction: beyond dopamine reward circuitry. Proc Natl Acad Sci U S A 2011; 108:15037-15042.
Wise RA. Roles for nigrostriatal--not just mesocorticolimbic--dopamine in reward and addiction. Trends Neurosci 2009;32:517-524.
Rowley HL, Butler SA, Prow MR, Dykes SG, Aspley S, Kilpatrick IC, et al. Comparison of the effects of sibutramine and other weightmodifying drugs on extracellular dopamine in the nucleus accumbens of freely moving rats. Synapse 2000;38:167-176.
Volkow ND, Fowler JS. Addiction, a disease of compulsion and drive: involvement of the orbitofrontal cortex. Cereb Cortex 2000;10:318-325.
Cruickshank CC, Dyer KR. A review of the clinical pharmacology of methamphetamine. Addiction 2009;104:1085-1099.
Barr AM, Panenka WJ, MacEwan GW, Thornton AE, Lang DJ, Honer WG, et al. The need for speed: an update on methamphetamine addiction. J Psychiatry Neurosci 2006;31:301-313.
Hill SK, Reilly JL, Harris MS, Rosen C, Marvin RW, Deleon O, et al. A comparison of neuropsychological dysfunction in first-episode psychosis patients with unipolar depression, bipolar disorder, and schizophrenia. Schizophr Res 2009;113:167-175.
Baethge C, Baldessarini RJ, Freudenthal K, Streeruwitz A, Bauer M, Bschor T. Hallucinations in bipolar disorder: characteristics and comparison to unipolar depression and schizophrenia. Bipolar Disord 2005;7:136-145.
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.